Barclays
MBRX icon

Barclays’s Moleculin Biotech MBRX Stock Holding History

Barclays’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73K Buy
+621
New +$1.59K ﹤0.01% 4888
2025
Q2 		– Sell
-14
Closed -$335 – 5429
2025
Q1 		$335 Buy
+14
New +$470 ﹤0.01% 5105
2021
Q1 		– Sell
-3
Closed -$5K – 4999
2020
Q4 		$5K Sell
3
-3
-50% -$5.32K ﹤0.01% 4782
2020
Q3 		$10K Buy
6
+5
+500% +$10.6K ﹤0.01% 5010
2020
Q2 		$1K Buy
+1
New +$2.37K ﹤0.01% 5474
2016
Q3 		– Sell
-1
Closed -$9K – 6717
2016
Q2 		$9K Buy
+1
New +$16.2K ﹤0.01% 5577

Other funds holding MBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EI
EFG International Zurich $5.46B AUM

Barclays's MBRX Position: Q2 2026 in Review

Barclays opened a new position in Moleculin Biotech (MBRX) in Q2 2026: 621 shares worth $1.73K. The stake represents ﹤0.01% of the portfolio and ranks #4888 among its holdings. This is a return to the name: Barclays previously reported a position in MBRX as recently as Q1 2025.

Barclays first reported a position in MBRX in Q2 2016 and has held it in 6 quarters since. The position peaked at $10K in Q3 2020. 18 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

  • Barclays held 621 shares of Moleculin Biotech worth $1.73K as of Q2 2026.
  • Moleculin Biotech was a new Barclays position in Q2 2026.
  • Moleculin Biotech made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4888 holding.
  • Barclays first reported a position in Moleculin Biotech in Q2 2016 and has held it in 6 quarters since.
  • Barclays's Moleculin Biotech position peaked at $10K in Q3 2020.
  • 18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.